Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VOLT01 (Levolta Pharmaceuticals, Inc.)
- Development stage
- Unknown
- Lead developer
- Levolta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
VOLT01 is a proprietary, novel, patented small molecule derivative of zoledronic acid being developed by Levolta Pharmaceuticals. As a bisphosphonate-based therapy, it is designed to regulate bone metabolism and is primarily being investigated for the treatment of knee osteoarthritis (KOA) and osteoporosis. Unlike traditional bisphosphonates that focus solely on bone resorption, VOLT01 is being evaluated for its potential as a disease-modifying osteoarthritis drug (DMOAD) by targeting subchondral bone remodeling and potentially exerting anti-inflammatory effects within the joint environment. It is currently in Phase 3 clinical development for knee osteoarthritis, where it is administered as a single-dose intravenous infusion.
- Other names
- zoledronic acid derivativezoledronic acid complex
02
Targets
FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on VOLT01 (Levolta Pharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VOLT01 (Levolta Pharmaceuticals, Inc.).